Webinar Overview
With increasing pressure to reduce time to market and produce high-confidence candidates with a strong probability for clinical success, demand is rising for earlier biologically relevant solutions to improve lead optimization, promote early attrition, and support translational success.
Enhanced candidate selection will help you deliver better therapies to patients, faster. As more opportunities become available to de-risk small molecule candidates during earlier discovery phases, novel in vitro technologies can be leveraged to mitigate potential liabilities and strengthen investor confidence.
In this webinar explore how novel technologies are elevating de-risking during drug discovery, and how and when to apply novel approaches to your pipeline.
You will learn:
- When to introduce new approaches to your drug discovery workstream
- How technologies such as cardiotoxicity assays, cell painting, 3D models, and cell microarray screening improve translational confidence
- To apply these strategies early in the screening cascade for faster delivery of better therapies
- How to develop novel in vitro models to support translational advances in drug discovery
Scientific Moderator
Sarah Gould, PhD
Director, Senior Principal Scientific Advisor
Charles River
Webinar Presenters
Mark Aspinall-O’Dea, PhD
Associate Director, Advanced Modalities
Charles River
Peter Racz, PhD
Group Leader, Biology
Charles River